News Sentiment

IRON sentiment intelligence

Disc Medicine Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 76.15 Week of 17 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-0.6% over one week, +7.6% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Going Deeper On Disc Medicine (NASDAQ:IRON)

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -0.6% Price digesting
Trend fit Trend inactive 7.6% over four weeks
Fair value 31.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 32
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 7
GlobeNewswire 6
Investing.com Nigeria 4
Investing.com 3
MT Newswires 3
Seeking Alpha 2
Quartr 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 10
Regulatory and legal 5
Analyst action 4
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
DirectorsTalk Interviews Direct company coverage

Disc Medicine, Inc. (IRON) Stock Analysis: Biotech Innovator With 36.52% Upside Potential

Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on treating serious hematologic disorders, with a market capitalization of $2.84 billion. The company shows a potential upside of 36.52% based on an average analyst target price of $101.55, d

Tone
Positive 80/100
Event
Analyst action
Published
21 Jul 2026 10:22
Source
DirectorsTalk Interviews
MSN Direct company coverage

Truist Securities Initiates Coverage of Disc Medicine (IRON) with Buy Recommendation

Truist Securities has begun coverage of Disc Medicine (IRON) with a positive "Buy" rating. This initiation of coverage suggests that Truist analysts see potential for growth or strong performance in the company's stock, influencing investor perception and potentially its stock pr

Tone
Positive 85/100
Event
Analyst action
Published
19 Jul 2026 21:09
Source
MSN
ACCESS Newswire Direct company coverage

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine, Inc. (NASDAQ: IRON) shareholders. This follows allegations that the company may have issued materially misleading business information, particularly after the FDA issued a Complete Respons

Tone
Negative 27/100
Event
Regulatory and legal
Published
19 Jul 2026 19:41
Source
ACCESS Newswire
Stock Traders Daily Direct company coverage

(IRON) as a Liquidity Pulse for Institutional Tactics

This article provides an AI-driven analysis of Disc Medicine Inc. (NASDAQ: IRON), highlighting conflicting sentiment across different time horizons and an exceptional 70.0:1 risk-reward setup. It details three distinct institutional trading strategies—Position Trading, Momentum B

Tone
Positive 80/100
Event
Balance sheet
Published
19 Jul 2026 13:41
Source
Stock Traders Daily
Quiver Quantitative Direct company coverage

Lobbying Update: $50,000 of DISC MEDICINE lobbying was just disclosed

DISC MEDICINE (IRON) recently disclosed $50,000 in lobbying expenditures for Q2 2026, focusing on FDA approvals for rare diseases. Insider trading activity for IRON shows significant sales by executives, while institutional investors have both added and decreased their positions.

Tone
Negative 39/100
Event
Market update
Published
17 Jul 2026 05:20
Source
Quiver Quantitative
GlobeNewswire Direct company coverage

Disc Medicine Investor News: If You Have Suffered Losses in

The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing the stock price to fall 22%. Investors who purchased Disc Medicine s

Tone
Negative 29/100
Event
Market update
Published
16 Jul 2026 07:10
Source
GlobeNewswire
Investing.com Direct company coverage

Cantor Fitzgerald reiterates Disc Medicine stock rating on pipeline catalysts

Cantor Fitzgerald reiterated an Overweight rating and $125 price target for Disc Medicine (NASDAQ:IRON), citing upcoming pipeline catalysts. The firm is bullish on bitopertin's Phase 3 study for EPP and X-linked protoporphyria, with data expected in Q4 2026, and also highlighted

Tone
Positive 71/100
Event
Analyst action
Published
15 Jul 2026 12:42
Source
Investing.com
Investing.com Direct company coverage

Disc Medicine CEO John Quisel sells $2.47m in shares

Disc Medicine CEO John Quisel sold approximately $2.47 million worth of shares on July 13, 2026, while simultaneously exercising stock options to acquire shares worth about $352,374. These transactions were executed under a Rule 10b5-1 trading plan. Following these sales and acqu

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 07:10
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Disc Medicine Inc For: 14 July By Investing.com

This article reports on a Form 4 filing for Disc Medicine Inc. on July 14. The content primarily consists of a brief announcement and various financial market data sections, news links, and promotional material from Investing.com.

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 07:10
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Disc Medicine (NASDAQ: IRON) CEO exercises options and sells 33,000 shares

Disc Medicine, Inc.'s CEO, John D. Quisel, reported exercising stock options for 33,000 shares and subsequently selling all 33,000 shares in open-market transactions on July 13, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted on March 12, 2026, with weight

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 06:47
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 144 Disc Medicine For: 13 July By Investing.com

This article from Investing.com announces a Form 144 filing for Disc Medicine, dated July 13. The brief piece includes a stock ticker for IRON and links to comment functionality, providing minimal specific information about the filing itself.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:41
Source
Investing.com Nigeria
Quartr Direct company coverage

Disc Medicine (IRON) H.C. Wainwright 27th Annual Global Investment Conference Summary

Disc Medicine presented at the H.C. Wainwright 27th Annual Global Investment Conference, providing an update on its lead asset, bitopertin, for red blood cell disorders. The company plans an NDA filing for bitopertin in October, with a PDUFA date in the second half of next year,

Tone
Positive 81/100
Event
Market update
Published
12 Jul 2026 08:11
Source
Quartr
Quartr Direct company coverage

Disc Medicine (IRON) Barclays 27th Annual Global Healthcare Conference Summary

Disc Medicine (IRON) presented at the Barclays 27th Annual Global Healthcare Conference, highlighting its strategic focus on severe hematologic disorders with three mid-to-late-stage clinical programs. The company's lead program, bitopertin, for erythropoietic protoporphyria (EPP

Tone
Positive 74/100
Event
Market update
Published
12 Jul 2026 08:11
Source
Quartr
GlobeNewswire Direct company coverage

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims on behalf of investors who suffered losses in Disc Medicine, Inc. (NASDAQ: IRON). The investigation stems from allegations that the company may have issued misleading business information, particularly after the FDA

Tone
Negative 18/100
Event
Regulatory and legal
Published
11 Jul 2026 15:01
Source
GlobeNewswire
TradingView Direct company coverage

Price to earnings forward of Disc Medicine, Inc. – BOATS:IRON

This page provides financial information for Disc Medicine, Inc. (IRON) on TradingView, specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of access and lists the financial data.

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 02:39
Source
TradingView
Investing.com Nigeria Direct company coverage

Disc Medicine COO Jonathan Yu sells $8,250 in stock By Investing.com

Disc Medicine's COO, Jonathan Yu, sold 100 shares of company stock for $8,250 on July 7, 2026, after exercising options at a lower price. This transaction was part of a pre-arranged Rule 10b5-1 trading plan. Despite the sale, Yu directly holds 54,324 shares and 23,747 derivative

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 05:41
Source
Investing.com Nigeria
Investing.com Nigeria Direct company coverage

Form 4 Disc Medicine Inc For: 9 July By Investing.com

This article reports on a Form 4 filing for Disc Medicine Inc., specifically relating to activity on July 9th. It is a brief administrative notice from Investing.com, providing basic information about the financial filing. The content focuses on the filing itself rather than prov

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 05:41
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Disc Medicine (IRON) COO trades 100 shares after option exercise under 10b5-1 plan

Disc Medicine, Inc.'s Chief Operating Officer, Jonathan Yen-Wen Yu, reported exercising stock options for 100 shares at $13.50 each and simultaneously selling 100 shares at an average price of $82.50 on July 7, 2026. These transactions were carried out under a pre-arranged Rule 1

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 05:11
Source
Stock Titan
Investing.com Direct company coverage

Disc Medicine COO Jonathan Yu sells $8,250 in stock

Disc Medicine COO Jonathan Yu sold 100 shares of the company's common stock for $8,250 on July 7, 2026, through a Rule 10b5-1 trading plan. This sale occurred simultaneously with the exercise of stock options to acquire 100 shares at a lower price. Following these transactions, Y

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 22:11
Source
Investing.com